BridGene Biosciences Showcases Pioneering Cancer Research at International Conference
BridGene Biosciences Showcases Pioneering Cancer Research at International Conference
BridGene Biosciences, a prominent figure in the field of biotechnology, announces its participation in the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled from October 22 to 26, 2025, in Boston, Massachusetts. The company will present three significant research studies, highlighting their latest advancements in targeting traditionally challenging oncology targets through small molecule drugs.
Groundbreaking Discoveries Presented
The company's key presentations will include:
1. A Novel Covalent FGFR3 Inhibitor: BridGene is set to unveil a highly potent and selective covalent inhibitor of FGFR3, a target often linked with aggressive cancer types. The research emphasizes the compound’s ability to bind irreversibly to a previously unexplored cysteine residue on FGFR3, leading to sustained inhibition of its activity. The findings indicate promising outcomes in cellular models that show strong antiproliferative effects and exceptional selectivity over other members of the FGFR family.
2. First-in-Class Covalent PAX8 Inhibitor: The second poster details the identification of BGP-31609, a covalent inhibitor that targets the DNA-binding domain of PAX8, a transcription factor implicated in ovarian cancer. The research finds that BGP-31609 can disrupt transcriptional activities affecting oncogenic targets, thereby demonstrating its potential as a therapeutic agent for PAX8-dependent malignancies.
3. IMTAC™ Chemoproteomics Platform: BridGene will also present findings on their proprietary IMTAC™ platform, a groundbreaking live-cell screening technology. This platform has enabled the discovery of covalent binders to various target classes, including GPCRs and phosphatases, by integrating a unique library of covalent small molecules with advanced chemical proteomics techniques.
The Future of Oncology Therapeutics
Dr. Ping Cao, CEO and co-founder of BridGene Biosciences, expressed enthusiasm about the discoveries, stating, "We're excited to present findings that not only validate the effectiveness of our IMTAC™ platform but also demonstrate how we can uncover hidden target binding sites that have historically been hard-to-drug. This research indicates significant potential avenues for developing treatments for complex cancers.”
The presentations will be part of the conference’s poster sessions. The scientific team from BridGene will be available for discussions following their presentations, reflecting their dedication to pushing the boundaries of small molecule drug discovery.
Conclusion
As BridGene continues to spearhead advancements in drug discovery for difficult targets, its contributions to the field of cancer research are set to expand. The company’s participation in this esteemed conference underscores its commitment to innovation and improving treatment options for patients globally. Furthermore, interested parties can find the research presentations on the AACR-NCI-EORTC conference website after the sessions conclude.
For further details, please visit BridGene Biosciences.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.